Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating Costs and Expenses:    
General and administrative $ 1,419,000 $ 1,393,000
Research and development 1,118,000 1,635,000
Total Operating Costs and Expenses 2,537,000 3,028,000
Loss from Operations (2,537,000) (3,028,000)
Other Income :    
Interest income 0 38,000
Total Other Income 0 38,000
Net Loss (2,537,000) (2,990,000)
Net Loss Attributable to Non-controlling Interest (1,000) (26,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (2,536,000) (2,964,000)
Effect of Series A Preferred Stock Price adjustment (7,402,000) 0
Net Loss Attributable to Common Stockholders $ (11,459,000) $ (3,430,000)
Net Loss Per Share - Basic and Dilutive $ (0.13) $ (0.20)
Weighted average number of shares outstanding during the period - Basic and Dilutive 90,807,693 17,093,920
Series A Preferred Stock [Member]    
Other Income :    
Preferred Stock Dividends, Income Statement Impact $ (24,000) $ (62,000)
Effect of Series A Preferred Stock Price adjustment 7,402,000  
Series B Preferred Stock [Member]    
Other Income :    
Net Loss Attributable to Non-controlling Interest 0 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0
Preferred Stock Dividends, Income Statement Impact $ (1,497,000) $ (404,000)